ID   585A1-C7 #3-3
AC   CVCL_C1G0
SY   585A1-C7-retained #3-3; C7 #3-3
DR   Wikidata; Q114310461
RX   Patent=US20200407693;
RX   PubMed=30853558;
CC   Population: Japanese.
CC   Knockout cell: Method=CRISPR/Cas9; HGNC; HGNC:4931; HLA-A.
CC   Knockout cell: Method=CRISPR/Cas9; HGNC; HGNC:4932; HLA-B.
CC   Knockout cell: Method=CRISPR/Cas9; HGNC; HGNC:4933; HLA-C (Note=1 of 2 alleles: C*12:02, leaving C*07:01 intact).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_DQ06 ! 585A1
SX   Male
AG   30-39Y
CA   Induced pluripotent stem cell
DT   Created: 22-09-22; Last updated: 19-12-24; Version: 6
//
RX   Patent=US20200407693;
RA   Hotta A., Xu H.-G., Kaneko S., Wang B.;
RT   "Method for producing low-antigenic cell.";
RL   Patent number US20200407693, 31-Dec-2020.
//
RX   PubMed=30853558; DOI=10.1016/j.stem.2019.02.005;
RA   Xu H.-G., Wang B., Ono M., Kagita A., Fujii K., Sasakawa N., Ueda T.,
RA   Gee P., Nishikawa M., Nomura M., Kitaoka F., Takahashi T., Okita K.,
RA   Yoshida Y., Kaneko S., Hotta A.;
RT   "Targeted disruption of HLA genes via CRISPR-Cas9 generates iPSCs with
RT   enhanced immune compatibility.";
RL   Cell Stem Cell 24:566-578.e7(2019).
//